This trial studies how well an imaging agent called I-124 M5A works in detecting colorectal cancer that has spread to the liver. The agent combines an antibody that finds cancer cells with a radioactive signal that makes them visible on scans. It targets patients with a specific type of cancer that may not be easily detected with standard imaging techniques. The M5A antibody has been extensively studied for its effectiveness in targeting colorectal cancer.